Journal of International Psychiatry

[Abstract] Objective: To explore the efficacy and side effects of ziprasidone combined with lithium carbonate in the treatment of manic episodes of bipolar disorder. How: A total of 90 patients with bipolar disorder with manic episodes from the Third People's Hospital of Fuyang City from January 2021 to December 2022 were selected and divided into the experimental group (Ziprasidone combined with lithium carbonate, n=45) and the control group (sodium valproate combined with carbonic acid, n=45) by random number table method. The clinical efficacy, Young mania rating scale (YMRS) score, recurrence rate, adverse reactions and serological indexes of the two groups were compared. Results: Clinical efficacy: The significant efficiency of control group (28.89%) was lower than that of experimental group (55.56%, P < 0.05). The total effective rate of the experimental group (97.78%) was higher than that of the control group (77.78%, P < 0.05), and there was no significant difference in blood lithium concentration between the two groups after treatment (P > 0.05).The concentrations of YMRS and Homocysteine (HCY) in the experimental group and control group after treatment were lower than before treatment (P < 0.05), and the concentrations in the experimental group were lower than those in the control group (P < 0.05). The recurrence rate of the experimental group was lower than that of the control group (P < 0.05). The rate of adverse reactions in the control group (13.34%) was lower than that in the experimental group (15.56%), but there was no statistical significance between the two groups (P > 0.05). Conclusion: Ziprasidone combined with lithium carbonate in the treatment of bipolar disorder with manic episode has good effect and less adverse reactions, so it can be widely used in clinical practice.

[Key words]: bipolar disorder; Manic attack; Ziprasidone; Lithium carbonate; YMRS score